Many clinical studies targeting EpCAM did not reach their primary endpoints in the past due to dose-limiting toxicities like pancreatitis (110, 111) or gastrointestinal-related adverse events (27, 112, 113). This evidence concerns the gene EPCAM and pancreatitis.